科创板IPO失败!问题一箩筐的长风药业最终折戟

星空财研
23 Oct 2024

全文2058字,阅读约需6分钟,帮我划重点划重点01长风药业在经历一年多的IPO之旅后最终折戟,这是其第二次尝试登陆科创板失败。02公司收入高度依赖单一产品布地奈德混悬液,毛利率低于同行,且波动剧烈。03尽管年年亏损,长风药业仍进行巨额股权激励和学术推广费支出,导致公司亏损加剧。04与此同时,公司估值在9个月内涨了近3倍,存在突击入股现象。05由于存在诸多问题,长风药业的IPO失败成为必然。以上...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10